{
    "nctId": "NCT00618124",
    "briefTitle": "A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together",
    "officialTitle": "A Phase 1 Safety And Pharmacokinetic Study Of SU011248 And Capecitabine In Patients With Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Solid Tumors, Breast Cancer, Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 77,
    "primaryOutcomeMeasure": "To determine the maximally tolerated dose of SU011248 (dosed continuously or on a 4/2 or 2/1 Schedule) when given in combination with capecitabine.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists\n* Patient has good performance status (ECOG 0 or 1)\n\nExclusion Criteria:\n\n* Prior treatment with either SU011248 or capecitabine.\n* Hypertension that cannot be controlled by medications",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}